Samsung Bioepis’ SB27 shows phase 3 equivalence to pembrolizumab in metastatic NSCLC

Coverage, in order

1. 3d ago
   Korea Biomedical Review South Korea obscure randomized trial

   Samsung Bioepis’ SB27 shows phase 3 equivalence to pembrolizumab in metastatic NSCLC

   Samsung Bioepis said Friday that its proposed Keytruda (pembrolizumab) biosimilar SB27 achieved a week 24 objective response rate (ORR) of 34.6 percent versus 37.9 percent with Keytruda in a phase 3 trial. The company said the results met the trial’s prespecified equivalence criteria. The trial enro

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.